# [225Ac]Ac-ETN029

Source: https://onco.cc/drugs/etn029/  
OnCo record `etn029` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

[225Ac]Ac-ETN029 is an experimental radioligand therapy from Mariana Oncology, in phase 1 trials for small cell lung cancer, large cell neuroendocrine carcinoma of the lung and neuroendocrine prostate cancer and other cancers.

## Summary

[225Ac]Ac-ETN029 (ETN029, 225Ac-ETN029, 111In-ETN029) is a radioligand therapy (actinium-225) from Mariana Oncology, with Novartis as acquirer. A radioligand therapy against DLL3, a cell-surface protein widely expressed across a range of cancers with limited expression on healthy cells; an indium-111 version is used for imaging. Its furthest stage is phase 1, for small cell lung cancer, large cell neuroendocrine carcinoma of the lung, neuroendocrine prostate cancer and gastroenteropancreatic neuroendocrine carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07006727 recruiting, sponsored by Novartis Pharmaceuticals. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: ETN029; 225Ac-ETN029; 111In-ETN029
- Tags: pipeline; ctgov-ingest
- Code: ETN029
- Modality: Radioligand therapy (actinium-225)
- Mechanism: A radioligand therapy against DLL3, a cell-surface protein widely expressed across a range of cancers with limited expression on healthy cells; an indium-111 version is used for imaging.

## Sources

- Mariana Oncology: marianaoncology.com: https://marianaoncology.com/programs-and-pipeline/
- Mariana Oncology: marianaoncology.com: https://marianaoncology.com/programs-and-pipeline/
- Mariana Oncology: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07006727
- ClinicalTrials.gov: trials of ETN029: https://clinicaltrials.gov/search?intr=ETN029

## Connected records

- cancers: [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Large cell neuroendocrine carcinoma of the lung](https://onco.cc/cancers/lung-lcnec/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Mariana Oncology](https://onco.cc/companies/mariana-oncology/), [Novartis](https://onco.cc/companies/novartis/)
- trials: [Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors](https://onco.cc/trials/nct07006727/)

---
JSON: https://onco.cc/api/v1/entities/etn029.json